Zobrazeno 1 - 10 of 26 pro vyhledávání: '"Prani Paka"'
1
Akademický článek
Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment
Autor: Caitlin Thomas, Sikander Ailawadhi, Rakesh Popat, David Kleinman, Melissa M. Ross, Boris Gorsh, Sarah Mulnick, Alicia O’Neill, Prani Paka, Maya Hanna, Nicolas Krucien, Alexa Molinari, Heather L. Gelhorn, Sue Perera
Publikováno v: Frontiers in Medicine, Vol 10 (2023)
IntroductionNewer treatment options for relapsed/refractory multiple myeloma (RRMM) with efficacy and safety profiles that differ from traditional therapies have facilitated personalized management strategies to optimize patient outcomes. In the cont
Externí odkaz: https://doaj.org/article/fb95510a02b3487884e1677723bf17e9
Zobrazit plný text záznamu
2
Akademický článek
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
Autor: Alexis Talbot, Arthur Bobin, Léa Tabone, Jérôme Lambert, Catherine Boccaccio, Cécile Deal, Marie-Odile Petillon, Olivier Allangba, Philippe Agape, Pierre Arnautou, Rakiba Belkhir, Sylvie Cailleres, Driss Chaoui, Marie-Lorraine Chrétien, Olivier Decaux, Samantha Schulmann, Laurent Frenzel, Lauris Gastaud, Antoine Huart, Cyrille Hulin, Lionel Karlin, Kamel Laribi, Ronan Le Calloch, Pascal Lenain, Margaret Macro, Salomon Manier, Lydia Montes, Stéphane Moreau, Philippe Moreau, Véronique Morel, James Norwood, Frédérique Orsini Piocelle, Aurore Perrot, Gian Matteo Pica, Philippe Rey, Anna Schmitt, Anne-Marie Stoppa, Mourad Tiab, Cyrille Touzeau, Valérie Vidal, Marguerite Vignon, Laure Vincent, Zoé Van De Wyngaert, Charles Zarnitsky, Naima Kerbouche, Prani Paka, Xavier Leleu, Bertrand Arnulf, Hervé Avet-Loiseau, IFM: Intergroupe Francophone du Myélome
Publikováno v: Haematologica, Vol 108, Iss 10 (2023)
Belantamab mafodotin (BM) is an anti-BCMA antibody-drug conjugate (GSK2857916) that represents an alternative option in multiple myeloma. We sought to assess the efficacy and safety of BM in a real-world setting in patients who benefited from an earl
Externí odkaz: https://doaj.org/article/b1c5d27182c748cbbd625be53da24488
Zobrazit plný text záznamu
3
Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study
Autor: Peter Feng Wang, Christopher W. Yee, Boris Gorsh, Miriam L. Zichlin, Prani Paka, Rachel H. Bhak, Natalie Boytsov, Anamika Khanal, Ahmed Noman, Maral DerSarkissian, Shannon Ferrante, Mei Sheng Duh
Publikováno v: Leukemia & Lymphoma. 64:398-406
Patients with relapsed/refractory multiple myeloma (RRMM) resistant to multiple drug classes remain a high unmet need population. This longitudinal retrospective cohort study assessed real-world treatment patterns and outcomes in adults with RRMM. Pa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::105959b19d90ec6e9cf1e839a4a42d6e
https://doi.org/10.1080/10428194.2022.2140284
Zobrazit plný text záznamu
5
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: IFM 2020-04 study
Autor: Alexis Talbot, Arthur Bobin, Léa Tabone, Jérôme Lambert, Catherine Boccaccio, Cécile Deal, Marie-Odile Petillon, Olivier Allangba, Philippe Agape, Pierre Arnautou, Rakiba Belkhir, Sylvie Cailleres, Driss Chaoui, Marie-Lorraine Chrétien, Olivier Decaux, Samantha Schulmann, Laurent Frenzel, Lauris Gastaud, Antoine Huart, Cyrille Hulin, Lionel Karlin, Kamel Laribi, Ronan Le Calloch, Pascal Lenain, Margaret Macro, Salomon Manier, Lydia Montes, Stéphane Moreau, Philippe Moreau, Véronique Morel, James Norwood, Frédérique Orsini Piocelle, Aurore Perrot, Gian Matteo Pica, Philippe Rey, Anna Schmitt, Anne-Marie Stoppa, Mourad Tiab, Cyrille Touzeau, Valérie Vidal, Marguerite Vignon, Laure Vincent, Zoé Van De Wyngaert, Charles Zarnitsky, Naima Kerbouche, Prani Paka, Xavier Leleu, Bertrand Arnulf, Hervé Avet-Loiseau, IFM: Intergroupe Francophone Du Myélome
Publikováno v: Haematologica.
Belantamab mafodotin (BM) is an anti-BCMA antibody-drug conjugate (GSK2857916) that represents an alternative option in multiple myeloma. We sought to assess the efficacy and safety in real-world of BM in patients who benefited from an early access p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5bdb5874a06d18b66bd9233c45f80594
https://doi.org/10.3324/haematol.2022.281772
Zobrazit plný text záznamu
10
Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study
Autor: Antoine Bessou, Xavier Colin, Julie De Nascimento, Will Sopwith, Shannon Ferrante, Boris Gorsh, Benjamin Gutierrez, Leah Sansbury, Jenny Willson, Sandhya Sapra, Prani Paka, Feng Wang
Publikováno v: The European Journal of Health Economics. 24:321-333
Background Real-world data on health care resource utilisation (HCRU) and costs for French patients with multiple myeloma (MM) are limited due to the quickly evolving MM treatment landscape. This retrospective, national-level study quantified the MM
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdc35048a9e07acf3151a90ad0b092b7
https://doi.org/10.1007/s10198-022-01463-9
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje